Molecular Cancer is delighted to announce the new thematic series entitled 'mRNA therapies and mRNA vaccines in cancer.'
Click here to view this collection.
Click here to access all thematic series published to date in Molecular Cancer.
2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer
Editor-in-Chief
Christophe Nicot, Kansas University Medical Center, USA
Aims and scope
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
Articles
-
-
mRNA therapeutics in cancer immunotherapy
-
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression
-
Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types
-
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling
-
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling
-
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
-
Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer
-
The complexity of NF-κB signaling in inflammation and cancer
-
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma
Featured Article: Role of the NLRP3 inflammasome in cancer
In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Recognising Editorial Excellence
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
What is trending?
Click here to see which articles published in Molecular Cancer have been shared the most in the past three months.
Follow
Annual Journal Metrics
-
Speed
48 days to first decision for reviewed manuscripts only
12 days to first decision for all manuscripts
118 days from submission to acceptance
19 days from acceptance to publication
Citation Impact
15.302 - 2-year Impact Factor
10.478 - 5-year Impact Factor
2.969 - Source Normalized Impact per Paper (SNIP)
4.581 - SCImago Journal Rank (SJR)Usage
2,248,311 Downloads
196 Altmetric mentions